Astellas Acquires Fezolinetant for Menopausal Symptoms in Ogeda Acquisition
By Natasha Piper
Pharma Deals Review: Vol 2017 Issue 4 (Table of Contents)
Published: 20 Apr-2017
DOI: 10.3833/pdr.v2017.i4.2239 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Astellas has agreed to acquire Ogeda thereby gaining a Phase II drug, fezolinetant, for the treatment of hot flushes related to menopause in a deal worth €800 M (US$853 M)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS